Hologic Announces Fourth Quarter and Fiscal 2009 Operati...(Non-GAAP adjusted earnings per share- ...),Health

Date:11/9/2009

Non-GAAP adjusted earnings per share- Diluted $0.28 (1) $0.30 (1) ===== ===== NET INCOME GAAP net income (loss) $34,940 $(144,374) Adjustments: Fair value write-up of acquired Third Wave inventory 83 3,933 Amortization of intangible assets acquired since fiscal 2006 51,805 31,968 Stock-based compensation associated with the termination of former Third Wave officers - 480 Operating charges relating to the closure of the Company's organic photoconductor drum coatings manufacturing operations in Shanghai and related costs 2,002 - Acquired in-process research and development - 195,200 Income tax effect primarily related to reconciling items (16,387)(2) (9,995)(3) ------- ------ Non-GAAP adjusted net income $72,443 $77,212 ======= ======= EBITDA Non-GAAP adjusted net income $72,443 Interest expense, net 16,283 Provision for income taxes 41,700 Depreciation and amortization not adjusted above 18,828 ------ Adjusted EBITDA $149,254 ======== EXPLANATORY NOTES: (1) Non-GAAP adjusted earnings per share was calculated based on 259,884 and 259,242 weighted average diluted shares outstanding for the three mont
'/>"/>

SOURCE Hologic, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients